Energy Expenditure (EE), a key diagnostic measurement for treatment of obesity, is measured via indirect calorimetry method through breath biomarkers of CO2 production and/or O2 consumption rates (VCO2 and/or VO2, respectively). Current technologies are limited due to prevailing designs requiring wearable facial accessories that present accuracy, precision, and usability concerns with regards to free living measurement. A novel medical device and smart home system, named Smart Pad, has been developed, with the capability of energy expenditure assessment via VCO2 measured from a room’s CO2 concentration. The system has 3 distinct capabilities: contactless EE measurement, air quality optimization via actuation of room ventilation, and efficiency optimization via ventilation actuation of only human-occupied environments. The Smart Pad shows accuracy of 90% for 14-19 minutes of resting measurement and accuracy of 90% for 4.8-7.0 minutes of exercise measurement after calibrating for air exchange rate (λ [hour-1]) using a reference method. Without reference instrument calibration, the Smart Pad system shows average accuracy of nearly 100% with correlations of Y=1.02X, R=0.761 for high resolution measurements and Y=1.06X, R=0.937 for averaged measurements over 50-60 minutes. In addition, the Smart Pad validation for contactless EE measurement has been performed in different environments, including a vehicle, medical office, a private office, and an ambulatory enclosure with rooms, ranging in volume from 3.1 m3 to 18.8m3. It was concluded that contactless EE measurements can be accurately performed in all tested scenarios with both low and high air exchange environments with λ ranging from 1.5 Hours-1 to 10.0 Hours -1. The system represents a new way to assess EE of individuals under free-living conditions in an unobstructive, passive, and accurate manner, and it is comparable or better in single breath gas measurement accuracy (with comparisons sourced from FDA data) than other medical devices (e.g. Vyntus CPXTM, MasterScreen CPXTM, Oxycon ProTM, and MedGemTM) which were 510(k) cleared by the FDA for prescription use in metabolic/cardiopulmonary diagnostics.

Americans spend upwards of 90% of their time indoors, hence indoor air quality (IAQ) and the impact of IAQ on human health is a major public health concern. IAQ can be negatively impacted by outdoor pollution infiltrating indoors, the emission of indoor pollutants, indoor atmospheric chemistry and poor ventilation. Energy saving measures like retrofits to seal the building envelope to prevent the leakage of heated or cooled air will impact IAQ. However, existing studies have been inconclusive as to whether increased energy efficiency is leading to detrimental IAQ. In this work, field campaigns were conducted in apartment homes in Phoenix, Arizona to evaluate IAQ as it relates to particulate matter (PM), carbonyls, and tobacco specific nitrosamines (TSNA).

To investigate the impacts of an energy efficiency retrofit on IAQ, indoor and outdoor air quality sampling was carried out at Sunnyslope Manor, a city-subsidized senior living apartment complex. Measured indoor formaldehyde levels before the building retrofit exceeded reference exposure limits, but in the long term follow-up sampling, indoor formaldehyde decreased for the entire study population by a statistically significant margin. Indoor PM levels were dominated by fine particles and showed a statistically significant decrease in the long term follow-up sampling within certain resident subpopulations (i.e. residents who reported smoking and residents who had lived longer at the apartment complex). Additionally, indoor glyoxal and methylglyoxal exceeded outdoor concentrations, with methylglyoxal being more prevalent pre-retrofit than glyoxal, suggesting different chemical pathways are involved. Indoor concentrations reported are larger than previous studies. TSNAs, specifically N'-nitrosonornicotine (NNN), 4-(methyl-nitrosamino)-4-(3-pyridyl)-butanal (NNA) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) were evaluated post-retrofit at Sunnyslope Manor. Of the units tested, 86% of the smoking units and 46% of the non-smoking units had traces of at least one of the nitrosamines.